David Rosenbaum

David Rosenbaum

Company: Ardelyx

Job title: Chief Development Officer


Discovery & Development of Tenapanor for the Treatment of Hyperphosphatemia in Patients with CKD on Dialysis: A Novel Blocker of Paracellular Phosphate Absorption 5:00 pm

Physiology of phosphate homeostasis and the cardiovascular sequelae of hyperphosphatemia in patients with kidney disease New mechanistic understandings of phosphate absorption and control Clinical development of tenapanor as a novel blocker of paracellular phosphate absorptionRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.